Cytek Biosciences (CTKB) Competitors $3.94 -0.08 (-1.99%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$3.94 0.00 (0.00%) As of 09/3/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CTKB vs. TXG, TRNS, EYPT, ALNT, AEHR, LAB, SENS, FEIM, MASS, and QSIShould you be buying Cytek Biosciences stock or one of its competitors? The main competitors of Cytek Biosciences include 10x Genomics (TXG), Transcat (TRNS), Eyepoint Pharmaceuticals (EYPT), Allient (ALNT), Aehr Test Systems (AEHR), Standard BioTools (LAB), Senseonics (SENS), Frequency Electronics (FEIM), 908 Devices (MASS), and Quantum-Si (QSI). These companies are all part of the "measuring and control equipment" industry. Cytek Biosciences vs. Its Competitors 10x Genomics Transcat Eyepoint Pharmaceuticals Allient Aehr Test Systems Standard BioTools Senseonics Frequency Electronics 908 Devices Quantum-Si 10x Genomics (NASDAQ:TXG) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations. Does the media favor TXG or CTKB? In the previous week, 10x Genomics had 13 more articles in the media than Cytek Biosciences. MarketBeat recorded 16 mentions for 10x Genomics and 3 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 1.65 beat 10x Genomics' score of 1.27 indicating that Cytek Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 10 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytek Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts prefer TXG or CTKB? 10x Genomics presently has a consensus price target of $13.54, suggesting a potential upside of 1.51%. Cytek Biosciences has a consensus price target of $5.60, suggesting a potential upside of 42.13%. Given Cytek Biosciences' higher possible upside, analysts clearly believe Cytek Biosciences is more favorable than 10x Genomics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 10x Genomics 1 Sell rating(s) 6 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.38Cytek Biosciences 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 Which has stronger earnings & valuation, TXG or CTKB? Cytek Biosciences has lower revenue, but higher earnings than 10x Genomics. Cytek Biosciences is trading at a lower price-to-earnings ratio than 10x Genomics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio10x Genomics$610.78M2.72-$182.63M-$0.70-19.06Cytek Biosciences$200.45M2.50-$6.02M-$0.05-78.80 Do insiders and institutionals have more ownership in TXG or CTKB? 84.7% of 10x Genomics shares are held by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are held by institutional investors. 10.0% of 10x Genomics shares are held by insiders. Comparatively, 10.3% of Cytek Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more volatility & risk, TXG or CTKB? 10x Genomics has a beta of 2, meaning that its stock price is 100% more volatile than the S&P 500. Comparatively, Cytek Biosciences has a beta of 1.36, meaning that its stock price is 36% more volatile than the S&P 500. Is TXG or CTKB more profitable? Cytek Biosciences has a net margin of -3.27% compared to 10x Genomics' net margin of -13.13%. Cytek Biosciences' return on equity of -1.66% beat 10x Genomics' return on equity.Company Net Margins Return on Equity Return on Assets 10x Genomics-13.13% -12.88% -10.03% Cytek Biosciences -3.27%-1.66%-1.30% Summary10x Genomics and Cytek Biosciences tied by winning 8 of the 16 factors compared between the two stocks. Get Cytek Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CTKB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTKB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTKB vs. The Competition Export to ExcelMetricCytek BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$526.71M$3.11B$5.77B$9.76BDividend YieldN/A2.28%6.66%4.49%P/E Ratio-78.8021.1082.3426.60Price / Sales2.50357.79502.89158.84Price / Cash119.3043.5325.7028.92Price / Book1.338.1310.916.56Net Income-$6.02M-$53.35M$3.28B$266.04M7 Day Performance-5.52%0.73%0.09%-0.89%1 Month Performance2.60%7.76%8.93%4.34%1 Year Performance-24.67%11.97%51.81%24.06% Cytek Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTKBCytek Biosciences2.2475 of 5 stars$3.94-2.0%$5.60+42.1%-26.9%$526.71M$200.45M-78.80500Positive NewsTXG10x Genomics4.1271 of 5 stars$14.07-1.6%$13.54-3.8%-42.1%$1.78B$610.78M-20.101,240Positive NewsTRNSTranscat4.1053 of 5 stars$91.20+0.9%$112.20+23.0%-34.7%$842.72M$278.42M63.781,245Positive NewsEYPTEyepoint Pharmaceuticals2.2788 of 5 stars$11.59-2.0%$25.38+118.9%+47.1%$815.41M$43.27M-4.32120ALNTAllient3.6276 of 5 stars$46.59-0.6%$35.00-24.9%+116.1%$794.14M$529.97M54.172,525Short Interest ↓AEHRAehr Test Systems2.3264 of 5 stars$24.59+35.9%N/A+81.5%$541.46M$58.97M-189.1490Gap UpHigh Trading VolumeLABStandard BioTools1.9755 of 5 stars$1.24-2.4%$1.55+25.0%-34.8%$485.13M$174.43M-3.88620SENSSenseonics1.7395 of 5 stars$0.46-0.3%$1.55+240.1%+20.8%$372.64M$25.47M-3.5190News CoverageFEIMFrequency Electronics2.1733 of 5 stars$30.81+6.2%N/A+127.8%$282.21M$69.81M12.47200Upcoming EarningsMASS908 Devices3.3593 of 5 stars$6.27-2.8%$8.00+27.6%+48.4%$231.30M$59.63M-11.6160News CoverageQSIQuantum-Si2.0393 of 5 stars$1.14flat$3.48+204.8%+18.9%$230.85M$3.06M-1.68150 Related Companies and Tools Related Companies 10x Genomics Alternatives Transcat Alternatives Eyepoint Pharmaceuticals Alternatives Allient Alternatives Aehr Test Systems Alternatives Standard BioTools Alternatives Senseonics Alternatives Frequency Electronics Alternatives 908 Devices Alternatives Quantum-Si Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTKB) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThis Massive Market is Ripe for Disruption by this NasdaqFanatics Hit $31B. This Nasdaq Company Is Building the Next Wave Fanatics built a merch empire by owning th...i2i Marketing Group, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Shadow Group” in Washington, DC Could Crash MarketNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredWashington prepares for warWhile the headlines obsess over overseas conflicts, Washington has been quietly preparing for something much b...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytek Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytek Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
